29Jun
29Jun
Vanguard Partners With Candidly For Student Loan Repayment Program
Vanguard has partnered with Candidly to offer retirement plan sponsors a student loan debt repayment program option for eligible employees. The financial wellness service will be available to Vanguard recordkeeping clients as an opt-in feature. Vanguard expects to make the Candidly platform available in the second half of 2022. Workers with student loan debt often have difficulty reaching their financial goals. Financial planning and saving for retirement are complicated, and can be delayed because of student loan debt, says Amber...
29Jun
ZetrOZ Shares Insights for Providers and Patients Seeking Insurance Coverage on Novel Medical Technologies for Advanced Treatments
New medical technologies bring better outcomes to patients and more efficiency to the U.S. healthcare industry, but some insurers and care providers slow its adoption, according to ZetrOZ Systems, a leading innovator and inventor of sustained acoustic medicine for soft tissue injury healing. With more than 100,000 patients treated, George K. Lewis, Ph.D. and CEO of ZetrOZ Systems said, ZetrOZ has learned that a key to winning insurance provider approval of novel medical devices and therapies is thorough advance communication...
29Jun
Vanguard Partners With Candidly For Student Loan Repayment Program
"Vanguard has partnered with Candidly to offer retirement plan sponsors a student loan debt repayment program option for eligible employees. The financial wellness service will be available to Vanguard recordkeeping clients as an opt-in feature. Vanguard expects to make the Candidly platform available in the second half of 2022. Workers with student loan debt often have difficulty reaching their financial goals. Financial planning and saving for retirement are complicated, and can be delayed because of student loan debt, says Amber...
25Jun
Strides Pharma jumps on positive outcome of COVID-19 vaccine trials
Strides Pharma Science rallied 7.70% to Rs 336.50 after the company's subsidiary Biolexis and Akston Biosciences announce encouraging top-line results from phase II/III trial of their thermostable 2nd gen COVID-19 vaccine. The vaccine was well tolerated, with no reported safety issues and is shelf-stable for over six months at room temperature at 25 celsius and potency for one month at 37 celsius. The interim analysis showed 91% seroconversion rate at day 56. The vaccine will be produced at Stelis Biopharma,...
25Jun
Biolexis and Akston Biosciences Announce Encouraging Top-Line Results from Phase II/III Trial of their Thermostable 2nd Gen COVID-19 Vaccine
Akston Biosciences Corporation and Biolexis, a Strides Group Company, today announced results from a Phase II/III clinical trial in India of the SARS-CoV-2 vaccine, AKS-452, in which 1,600 healthy volunteers participated – 100 in an open-label bridging study and 1,500 in Phase II/III, double-blind, placebo-controlled trial. An interim analysis of this data shows no significant safety issues and a 91% seroconversion rate at Day 56. Volunteers in the bridging study had antibody titers that persisted at statistically-significant high levels through...
16Jun
FutureFuel.io Acquires College Finance Company to Expand Beyond Student Debt, Rebrands to Candidly
FutureFuel.io, the market's most comprehensive student debt management platform, today announced the acquisition of College Finance Company, the leading multi-lender marketplace for education financing. The company also announced a complete rebrand of its corporate identity, including a new logo, updated visual brand elements, and a new company name: Candidly. Read more >>
16Jun
Astrocyte Announces Initiation of First-In-Human Phase 1 Study of the Promising Stroke and Traumatic Brain Injury Therapeutic, AST-004
Astrocyte Pharmaceuticals Inc., a drug discovery and development company advancing novel cerebroprotective therapeutics for patients with brain injuries, announced that the Company’s first-in-human Phase 1 clinical study initiated today with the dosing of a first subject with AST-004. The promising investigational therapeutic, AST-004, is being advanced as a potential acute treatment for stroke and traumatic brain injury (TBI) victims, and as a chronic treatment for neurodegenerative diseases like Alzheimer’s. AST-004 has demonstrated a broad range of cerebroprotective efficacy when treating...
06Jun
Wasabi Technologies Doubles Down on APAC Expansion with Singapore Storage Region
Wasabi Technologies, the hot cloud storage company, reaffirmed its commitment to the Asia-Pacific market with the opening of a new storage region located in Singapore. This marks Wasabi’s 13th storage region globally and its fourth in APAC, following Tokyo, Osaka, and most recently Sydney, as the company scales to meet the demand for high-performance, affordable cloud storage, and to be in closer proximity to its expansive customer and partner network. Read more >>
04Jun